<DOC>
	<DOCNO>NCT03077438</DOCNO>
	<brief_summary>The aim trial evaluate immunogenicity describe safety MenACYW conjugate vaccine compare MENVEO® healthy child 2 9 year age United States . Primary objective : - To demonstrate non-inferiority vaccine seroresponse meningococcal serogroups A , C , Y , W follow administration single dose MenACYW conjugate vaccine compare observe follow administration single dose MENVEO® child age 2 9 year . Secondary objective : - To compare hSBA antibody geometric mean titer ( GMTs ) meningococcal serogroups A , C , Y , W follow administration MenACYW conjugate vaccine observe following administration MENVEO® child 2 9 year age - To evaluate hSBA antibody GMTs meningococcal serogroups A , C , Y , W follow administration MenACYW conjugate vaccine observe following administration MENVEO® child 2 5 year age , child 6 9 year age , respectively . - To evaluate hSBA vaccine seroresponse meningococcal serogroups A , C , Y , W 30 day ( +14 day ) post-vaccination child 2 5 year age , child 6 9 year age , respectively . Observational objective : - To describe safety profile MenACYW conjugate vaccine license MENVEO® .</brief_summary>
	<brief_title>Study Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Children Aged 2 9 Years</brief_title>
	<detailed_description>Healthy participant enrol , randomize , receive single dose either MenACYW conjugate vaccine MENVEO® . All participant assess immunogenicity baseline ( pre-vaccination ) Visit 2 ( post-vaccination ) . Safety information collect post vaccination throughout entire study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 9 year day inclusion Assent form sign date participant ( required local regulation ) inform consent form ( ICF ) sign date parent ( ) guardian Participant parent/guardian able attend schedule visit comply trial procedure Participant pregnant , lactating , childbearing potential use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination . To consider nonchildbearing potential , female must premenarche Participation 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week ( 28 day ) precede trial vaccination plan receipt vaccine prior Visit 2 except influenza vaccination , may receive least 2 week study investigational vaccine . This exception include monovalent , multivalent , live , attenuate influenza vaccine Previous vaccination meningococcal disease either trial vaccine another vaccine ( ie. , mono polyvalent , polysaccharide , conjugate meningococcal vaccine contain serogroups A , C , Y , W ; meningococcal B serogroup contain vaccine ) Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial ( specifically , limit , participant persistent complement deficiency , anatomic functional asplenia , participant travel country high endemic epidemic disease ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Verbal report thrombocytopenia , contraindicate intramuscular vaccination Investigator 's judgment Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Investigator 's opinion Personal history GuillainBarré syndrome Personal history Arthuslike reaction vaccination tetanus toxoidcontaining vaccine Chronic illness , opinion Investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord Investigator 's judgment ) day vaccination febrile illness ( temperature ≥100.4°F ) . A prospective participant include study condition resolve febrile event subside Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw Identified natural adopt child Investigator employee direct involvement propose study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>MenACYW conjugate vaccine</keyword>
	<keyword>MENVEO®</keyword>
</DOC>